Global Tumor Ablation Market to Grow at a CAGR of 13.30% Through 2032, Driven by Rising Cancer Incidence and Demand for Minimally Invasive Therapies | DelveInsight

The tumor ablation market is poised for substantial growth through 2032, fueled by the increasing global cancer burden and growing demand for less invasive, targeted treatment options. Tumor ablation-using thermal or non-thermal techniques such as radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation (IRE)-has emerged as a crucial modality for treating inoperable tumors or patients unfit for surgery, particularly in liver, kidney, lung, bone, and soft tissue cancers.

The market is being driven by several clinical advantages of ablation therapies: reduced complications, shorter hospital stays, and faster recovery compared to conventional surgical oncology. Additionally, advancements in image-guided techniques (CT, ultrasound, MRI) and ablation probes are improving precision and procedural outcomes, thereby expanding physician confidence and patient acceptance. The integration of AI and robotic systems in interventional oncology is also streamlining tumor targeting and therapy planning.

DelveInsight's Tumor Ablation Market Insights, Competitive Landscape, and Market Forecast - 2032 provides an in-depth analysis of market drivers, barriers, and emerging opportunities across geographies, including the US, EU4, the UK, Japan, and China. The report segments the market by technology type, application area, end-user, and procedure setting, along with insights into reimbursement scenarios, regulatory pathways, and clinical adoption trends.

Key players such as Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc. and others are leading the market through aggressive R&D investments, strategic acquisitions, and global expansion. With oncology becoming increasingly personalized and patient-centric, the tumor ablation market is set to evolve as a vital component of multidisciplinary cancer care, offering effective, outpatient-friendly solutions for localized tumors.

Explore the latest trends and growth drivers in the tumor ablation market-download your sample report now https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Tumor Ablation Market Report
• The global tumor ablation market was valued at USD 1,703.26 million in 2024 and is expected to grow at a CAGR of 13.30% from 2025 to 2032, reaching USD 4,595.68 million by 2032.
• As per DelveInsight estimates, North America is anticipated to dominate the global tumor ablation market during the forecast period.
• Notable tumor ablation companies such as Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott., Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew, Hologic, Inc., and several others are currently operating in the tumor ablation market.
• In June 2025, UroGen Pharma received FDA approval for ZUSDURI, the first and only treatment for adults with recurrent LG-IR-NMIBC. The drug combines mitomycin with UroGen's RTGel® technology for sustained release and effective tumor ablation. Approval was based on Phase III ENVISION trial results, showing a 78% complete response at 3 months, with 79% of those patients remaining event-free after 12 months.
• In December 2024, AngioDynamics received FDA clearance for its NanoKnife system for prostate cancer ablation. The device uses high-voltage electrical pulses to destroy tissue without heat, reducing the risk of thermal damage. Its non-radiation, pulsed field approach is similar to emerging cardiac ablation technologies.
• In March 2024, Medtronic received FDA clearance for OsteoCoolTM 2.0 bone tumor ablation system.
• In January 2024, Techsomed Medical Technologies received FDA De Novo clearance for BioTraceIO, the first ultrasound-based liver ablation software cleared for Tissue Response Prediction. The tool helps physicians visualize ablated areas in real time during liver tumor procedures.

To read more about the latest highlights related to the tumor ablation market, get a snapshot of the key highlights entailed in the global tumor ablation market report here https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Tumor Ablation Overview
Tumor ablation is a minimally invasive procedure used to destroy cancerous tissues by applying extreme heat, cold, or other energy sources directly to the tumor site. Common ablation techniques include radiofrequency ablation (RFA), microwave ablation (MWA), cryoablation, and irreversible electroporation (IRE), each tailored to specific tumor types, sizes, and locations. Primarily used for liver, kidney, lung, bone, and soft tissue cancers, tumor ablation offers an effective alternative for patients who are not ideal candidates for surgery. It is often performed under image guidance (CT, ultrasound, or MRI), ensuring precision and minimal damage to surrounding healthy tissues. The benefits of tumor ablation include reduced hospital stays, quicker recovery times, fewer complications, and the potential for repeat treatments. As technology evolves, tumor ablation is playing an increasingly critical role in modern oncology, particularly within multidisciplinary and palliative care strategies.

Tumor Ablation Market Insights
North America is projected to dominate the global tumor ablation market in 2024, driven by a high cancer burden-especially liver, kidney, and lung cancers-and growing demand for minimally invasive treatments. According to GLOBOCAN (2024), kidney cancer cases in the region are expected to rise from 79,800 in 2022 to 103,000 by 2045, while total cancer cases are projected to grow from 2.67 million to 3.83 million in the same period.

The region benefits from advanced healthcare infrastructure, strong R&D investments, and favorable reimbursement policies. The widespread adoption of minimally invasive procedures like radiofrequency, microwave, and cryoablation offers shorter recovery times and better patient outcomes, especially for those ineligible for traditional surgery.

Technological advancements and FDA approvals continue to fuel market growth. For instance, in November 2022, Baird Medical received FDA clearance for a microwave ablation device for thyroid nodules, expanding treatment options and reflecting ongoing innovation. These factors collectively position North America as a leading force in the tumor ablation market.

To know more about why North America is leading the market growth in the tumor ablation market, get a snapshot of the tumor ablation market outlook here https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Tumor Ablation Market Dynamics
According to the World Cancer Research Fund (2024), over 866,000 new liver cancer cases were reported globally in 2022. GLOBOCAN data further indicates that global kidney cancer cases reached 435,000 in the same year, projected to rise to 693,000 by 2045. These trends are fueling demand for tumor ablation techniques like radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation, especially for localized tumors in the liver and kidneys, where surgery may be risky or unsuitable.

Liver cancer, particularly hepatocellular carcinoma (HCC), and renal cell carcinoma are commonly treated with ablation when surgery isn't an option, offering organ-sparing and less invasive alternatives. The global market is also benefiting from strategic industry moves. For instance, in April 2023, Compal Electronics introduced a new RFA system targeting non-resectable liver lesions.

Despite its promise, the tumor ablation market faces limitations-such as potential complications (bleeding, infection, or tissue damage) and reduced efficacy in advanced or metastatic cancers-where more comprehensive treatments are often needed. Nonetheless, rising incidence rates and technological advances are expected to drive strong market growth through 2032.

Get a sneak peek at the tumor ablation market dynamics @ https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Coverage: Global
Study Period: 2022 to 2032
Tumor Ablation Market CAGR: ~13.30%
Key Tumor Ablation Companies: Medtronic PLC, Stryker, Baird Medical Devices Inc., Siemens Healthineers AG, Compal Electronics, Novian Health Inc., Boston Scientific, Merit Medical Systems, Johnson & Johnson, Abbott., Olympus Corporation, Bioventus Inc., AngioDynamics, Mermaid Medical, HealthTronics, Inc., HealthTronics, Inc., AtriCure, Inc., Hologic, Inc., Smith & Nephew, Hologic, Inc., and others.

Tumor Ablation Market Segmentation
Market Segmentation By Technology: Radiofrequency Ablation (RFA), Microwave Ablation (MWA), Cryoablation, Irreversible Electroporation (IRE), High-Intensity Focused Ultrasound (HIFU), and others.
Market Segmentation By Treatment Type: Surgical Ablation, Laparoscopic Ablation, and Percutaneous Ablation.
Market Segmentation By Indication: Liver Cancer, Lung Cancer, Kidney Cancer, Breast Cancer, Bone Metastasis, and others.
Market Segmentation By End-User: Hospitals & Clinics, Cancer Care Centers, and others.
Market Segmentation By Geography: North America, Europe, Asia-Pacific, and Rest of the World.

Which MedTech key players in the tumor ablation market are set to emerge as the trendsetter, explore @ https://www.delveinsight.com/report-store/tumor-ablation-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Tumor Ablation Market Report Introduction
2. Tumor Ablation Market Executive Summary
3. Competitive Landscape
4. Regulatory Analysis
5. Tumor Ablation Market Key Factors Analysis
6. Tumor Ablation Market Porter's Five Forces Analysis
7. Tumor Ablation Market Layout
8. Tumor Ablation Market Company and Product Profiles
9. KOL Views
10. Project Approach
11. About DelveInsight
12. Disclaimer & Contact Us

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.

Our expert healthcare consulting services offer in-depth market analysis, helping businesses accelerate growth and navigate challenges with actionable, results-driven strategies.

This release was published on openPR.